O
OVAX
Biotech & Life Sciences · Houston, United States · Founded 2023
Fentanyl vaccine technologies to prevent overdoses, focusing on prediction, prevention, and protection MoreLess
OVAX is at the forefront of developing vaccine technologies aimed at combating the fentanyl crisis by preventing overdoses before they occur. The company targets the healthcare sector, specifically addressing the needs of individuals at risk of opioid addiction and overdose. OVAX operates within the pharmaceutical and biotechnology markets, leveraging scientific research and innovation to create solutions that save lives. The business model revolves around the development and potential commercialization of vaccines, such as the OVAX 100 and OVAX 200, which are designed to block the effects of fentanyl. Revenue generation is anticipated through partnerships, licensing agreements, and direct sales to healthcare providers and government entities. The company's mission is underscored by a commitment to public health and safety, with a focus on prediction, prevention, and protection against opioid-related harm. Keywords: fentanyl, vaccine, overdose prevention, healthcare, biotechnology, pharmaceutical, addiction, public health, opioid crisis, safety.
Company overview
OVAX company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2023
- Headquarters
- Houston, United States
- Employees
- 19
- Open positions
- 1
- Dealroom signal
- 83.6
Valuation & funding
OVAX funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jun 2026 | $0 | — | SRx Health Solutions | ↗ |
| EARLY VCOther financing | Jun 2024 | $10M | $40M | Undisclosed | — |
| SPINOUTOther financing | Jan 2023 | $0 | — | Children’s Hospital Boston | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 19 |
| 2025 | 16 |
Growth signals
OVAX website traffic
Latest recorded traffic for OVAX is 3.4K monthly website visits, down 20.9% over the last three months. OVAX's team grew 18.8% over the past year.
Hiring
Open positions at OVAX
Current openings linked to this company in Dealroom.
Comparisons
OVAX compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
OVAX's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on OVAX's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where OVAX has talent and traffic
team presence
In the news
Latest news about OVAX
Recent press, funding announcements, and product moves mentioning OVAX — open to read from the original sources.
Market sentiment
What the market is saying about OVAX
An AI-synthesized read of the highest-engagement posts about OVAX on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OVAX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.